Health experts and pharmceutical giants have expressed concerns about President Donald Trump possibly introducing 'major' ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Trump’s latest tariff vow threatens to disrupt supplies of obesity drugs such as Mounjaro and Wegovy as pharma giants face ...

Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

The US president vows "major" tariffs on imported medicines - raising fears of an increase in costs for Americans.

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

A federal commission is calling for $15 billion in new financing to reinforce U.S. biotech leadership amid competition from ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...